TLX — Telix Pharmaceuticals Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapFalling Star

Annual balance sheet for Telix Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	ARS	ARS	ARS	Interim Report	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	fx Final	fx Final	fx Final	fx Final	fx Final
Cash
Cash and Short Term Investments	60	16	79.3	83.9	439
Net Total Accounts Receivable
Net Total Receivables	10.9	15.1	31.3	49.3	98.4
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	72	34.5	118	158	568
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	3.71	4.59	12.8	20.8	33.6
Net Goodwill
Net Intangible Assets
Long Term Investments
Long Term Notes Receivable
Other Long Term Assets
Total Assets	121	79.7	174	276	938
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	15.4	27.6	58.3	112	205
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Total Other Liabilities
Total Liabilities	60.6	78.2	119	175	587
Common Stock
Retained Earnings (Accumulated Deficit)
Unrealized Gain / Loss
Other Equity
Total Equity	60.8	1.57	54.5	101	352
Total Liabilities & Shareholders' Equity	121	79.7	174	276	938
Total Common Shares Outstanding